Payment overview · 2025
General Payments
$7,368.83
55 reported records · 12 companies
Healthcare provider profile · identity verified
Bella Kushnir, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1770743320
Verified facts
What the public records show
CMS Open Payments records show Bella Kushnir, M.D. received $7,368.83 in general payments during 2025 across 55 reported records.
ABBVIE INC. accounted for 85.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Linzess, Ozempic, Prolia, Rybelsus, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Prolia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $6,264.60 | 85.0% | 14 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $196.25 | 2.7% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $181.40 | 2.5% | 8 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $150.43 | 2.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $147.43 | 2.0% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $111.70 | 1.5% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $76.01 | 1.0% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.85 | 1.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.77 | 0.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.54 | 0.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $44.44 | 0.6% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.41 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,000.00 | 4 |
| Food and Beverage | $1,368.83 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $6,215.35 | 12 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $196.25 | 6 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $150.43 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $147.43 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $112.48 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $111.70 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $88.27 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $76.53 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $76.01 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $70.85 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.92 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $68.92 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $64.77 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.25 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.54 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $44.44 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 104 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 141 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 155 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 47 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 83 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
104 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
155 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
141 | 23 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
47 | 29 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
141 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
83 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
141 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 428 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 402 | 89 |
| Losartan Potassium | Losartan Potassium | 398 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 385 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 358 | 69 |
| Omeprazole | Omeprazole | 356 | 71 |
| Vascepa | Icosapent Ethyl | 354 | 66 |
| Diclofenac Sodium | Diclofenac Sodium | 305 | 56 |
| Metformin Hcl | Metformin Hcl | 224 | 50 |
| Gabapentin | Gabapentin | 223 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 35 |
| Famotidine | Famotidine | 212 | 54 |
| Simvastatin | Simvastatin | 176 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 34 |
| Linzess | Linaclotide | 155 | 30 |
| Lisinopril | Lisinopril | 150 | 35 |
| Meloxicam | Meloxicam | 147 | 60 |
| Icosapent Ethyl | Icosapent Ethyl | 145 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 27 |
| Eliquis | Apixaban | 141 | 26 |
| Synthroid | Levothyroxine Sodium | 141 | 23 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 137 | 44 |
| Jardiance | Empagliflozin | 125 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 51 |
| Alendronate Sodium | Alendronate Sodium | 107 | 23 |
| Creon | Lipase/Protease/Amylase | 104 | 28 |
| Ezetimibe | Ezetimibe | 103 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 22 |
| Carvedilol | Carvedilol | 100 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 33 |
| Allopurinol | Allopurinol | 99 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 99 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 97 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 25 |
| Furosemide | Furosemide | 95 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 17 |
| Single Use Swab | Alcohol Antiseptic Pads | 90 | 22 |
| Diclofenac Sodium Er | Diclofenac Sodium | 87 | 14 |
| Mounjaro | Tirzepatide | 85 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 26 |
| Rybelsus | Semaglutide | 83 | 14 |
| Jentadueto | Linagliptin/Metformin Hcl | 80 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 80 | 21 |
| Ammonium Lactate | Ammonium Lactate | 77 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 76 | 20 |
| Metformin Hcl Er | Metformin Hcl | 75 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 19 |
| Meclizine Hcl | Meclizine Hcl | 72 | 23 |
| Tradjenta | Linagliptin | 72 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 14 |
| Lidocaine | Lidocaine | 62 | 15 |
| Valsartan | Valsartan | 61 | 13 |
| Procto-Med Hc | Hydrocortisone | 60 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 57 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 57 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 17 |
| Alcohol Pads | Alcohol Antiseptic Pads | 53 | 14 |
| Naproxen Sodium | Naproxen Sodium | 52 | 13 |
| Ranolazine Er | Ranolazine | 49 | suppressed |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 47 | 12 |
| Hydrocortisone | Hydrocortisone | 47 | 13 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Prolia | Denosumab | 47 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | suppressed |
| Finasteride | Finasteride | 45 | suppressed |
| Ozempic | Semaglutide | 45 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 41 | 12 |
| Atenolol | Atenolol | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 40 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Dexilant | Dexlansoprazole | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 38 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 38 | suppressed |
| Baclofen | Baclofen | 37 | 12 |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Telmisartan | Telmisartan | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 26 |
| Folic Acid | Folic Acid | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 14 |
| Glimepiride | Glimepiride | 30 | suppressed |
| Loperamide | Loperamide Hcl | 30 | 12 |
| Cephalexin | Cephalexin | 29 | 25 |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | 12 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Praluent Pen | Alirocumab | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | 12 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 25 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Ibu | Ibuprofen | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 12 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 16 |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Neomycin-Bacitracin-Poly-Hc | Neomycin/Bacit/P-Myx/Hydrocort | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | 11 |
| Nystatin | Nystatin | 15 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Ramipril | Ramipril | 13 | suppressed |
| Webcol | Alcohol Antiseptic Pads | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Nisoldipine | Nisoldipine | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,368.83 · 55 records | ABBVIE INC. | CAMZYOS, CAPVAXIVE, CREON, ELIQUIS, EVENITY, GARDASIL 9, IBSRELA, LEQVIO, LINZESS, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, XIFAXAN, ZAVZPRET, ZENPEP | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error